Kamada Obtains Tax Ruling for $0.25 Dividend per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy KMDA?
Kamada announced that it has obtained a tax ruling from the Israel Tax Authority with respect to the cash dividend of 25c per share on the company's ordinary shares announced on March 11. As a result of the ruling, shareholders who hold company shares as of the record date that trade such shares on the Nasdaq Stock Market and are residents of a country with which Israel has a tax treaty may be eligible for a reduced Israeli withholding tax rate on their share of the dividend, in comparison to the generally applicable Israeli withholding tax rate under certain terms and conditions. The company has appointed IBI Trust Management to serve as a processing agent in connection with the distribution of the Nasdaq Dividend.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KMDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KMDA
Wall Street analysts forecast KMDA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.470
Low
13.00
Averages
14.00
High
15.00
Current: 8.470
Low
13.00
Averages
14.00
High
15.00
About KMDA
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kamada Secures Tax Ruling for Dividend Distribution
- Dividend Announcement: Kamada announced a cash dividend of $0.25 per share, totaling approximately $14.4 million, to be paid on April 7, 2026, to shareholders of record as of March 23, 2026, demonstrating the company's commitment to shareholder returns.
- Tax Ruling Impact: The ruling from the Israel Tax Authority allows eligible Nasdaq shareholders to benefit from a reduced withholding tax rate, which is expected to enhance actual returns for shareholders and bolster investor confidence.
- Compliance Requirements: Nasdaq shareholders must submit necessary documentation to the Tax Agent by May 9, 2026, to qualify for the reduced withholding tax rate, making compliance critical to managing their tax liabilities effectively.
- Appointment of Tax Agent: Kamada appointed IBI Trust Management as the tax agent to facilitate the tax-related processes for dividend distribution, aiming to streamline procedures and enhance shareholder convenience.
See More
Kamada Receives FDA Approval for San Antonio Plasma Center
- FDA Approval: Kamada's plasma collection center in San Antonio, Texas, has received FDA approval following an on-site inspection in February 2026, marking a significant milestone in the company's expansion into the U.S. market.
- Capacity and Revenue Potential: The center features 50 donor beds and can produce up to 50,000 liters annually at full capacity, with projected annual revenues of $8 to $10 million, significantly enhancing the company's revenue base and market competitiveness.
- International Expansion Plans: Following FDA clearance, Kamada plans to pursue EMA inspection and approval, demonstrating the company's strategic intent to expand in global markets and further diversify its revenue streams.
- Future Growth Expectations: Kamada forecasts double-digit profitable growth in 2026, and with its biosimilars pipeline, the company is positioned for sustained profitability and enhanced market standing in the future.
See More
Kamada Receives FDA Approval for Plasma Sales in Texas
- FDA Approval: Kamada's plasma collection center in San Antonio, Texas, has received FDA approval, marking the commencement of commercial sales and significantly enhancing the company's competitive position in the plasma market.
- Annual Collection Capacity: The center has an annual collection capacity of approximately 50,000 liters of plasma, with projected annual revenues of $8 million to $10 million at full capacity, further strengthening the company's financial performance.
- Market Position Enhancement: The San Antonio center is expected to be one of the largest specialty plasma collection centers in the U.S., which not only elevates Kamada's market position but also lays the groundwork for future expansion.
- Future Development Plans: Following FDA approval, Kamada intends to seek subsequent inspection and approval from the European Medicines Agency, demonstrating its ambition for international expansion and commitment to the global market.
See More
KAMADA LTD - SAN ANTONIO CENTER AUTHORIZED TO START COMMERCIAL SALES OF NORMAL SOURCE PLASMA
- Commercial Sales Announcement: The Kamada San Antonio Center has been cleared to commence commercial sales of normal source plasma.
- Significance of Plasma Sales: This development marks a significant step in the center's operations, potentially impacting the supply of plasma-derived therapies.
See More
Kamada Receives FDA Approval for Plasma Collection Center in San Antonio, Texas
Announcement of New Facility: Kamada has announced the approval of its new plasma collection center in San Antonio, Texas.
Significance of the Center: The facility aims to enhance the company's capabilities in plasma collection, which is crucial for their therapeutic products.
See More
Major Averages Decline Amid Oil Price Volatility
- Market Impact from Oil Prices: The major averages, including the Dow, fell over 400 points as oil prices surged above $100 earlier in the week, reflecting traders' concerns over volatile energy prices and geopolitical tensions in the Middle East.
- IEA's Strategic Release: The International Energy Agency's decision to release approximately 400 million barrels from strategic reserves aims to stabilize energy markets following supply shocks due to conflicts, which could help mitigate extreme oil price fluctuations.
- Inflation Data Reaction: Recent inflation data showed a 0.3% month-over-month increase in the consumer price index and a 2.4% year-over-year rise, both aligning with consensus expectations, indicating persistent inflationary pressures that may influence future monetary policy decisions.
- Escalating Geopolitical Risks: U.S. forces sunk several Iranian ships near the Strait of Hormuz, heightening the fragility of global energy supply routes and contributing to unstable market sentiment, prompting investors to adopt a cautious stance regarding future market movements.
See More
Kamada Secures Tax Ruling for Dividend Distribution
- Dividend Announcement: Kamada announced a cash dividend of $0.25 per share, totaling approximately $14.4 million, to be paid on April 7, 2026, to shareholders of record as of March 23, 2026, demonstrating the company's commitment to shareholder returns.
- Tax Ruling Impact: The ruling from the Israel Tax Authority allows eligible Nasdaq shareholders to benefit from a reduced withholding tax rate, which is expected to enhance actual returns for shareholders and bolster investor confidence.
- Compliance Requirements: Nasdaq shareholders must submit necessary documentation to the Tax Agent by May 9, 2026, to qualify for the reduced withholding tax rate, making compliance critical to managing their tax liabilities effectively.
- Appointment of Tax Agent: Kamada appointed IBI Trust Management as the tax agent to facilitate the tax-related processes for dividend distribution, aiming to streamline procedures and enhance shareholder convenience.
See More
Kamada Receives FDA Approval for San Antonio Plasma Center
- FDA Approval: Kamada's plasma collection center in San Antonio, Texas, has received FDA approval following an on-site inspection in February 2026, marking a significant milestone in the company's expansion into the U.S. market.
- Capacity and Revenue Potential: The center features 50 donor beds and can produce up to 50,000 liters annually at full capacity, with projected annual revenues of $8 to $10 million, significantly enhancing the company's revenue base and market competitiveness.
- International Expansion Plans: Following FDA clearance, Kamada plans to pursue EMA inspection and approval, demonstrating the company's strategic intent to expand in global markets and further diversify its revenue streams.
- Future Growth Expectations: Kamada forecasts double-digit profitable growth in 2026, and with its biosimilars pipeline, the company is positioned for sustained profitability and enhanced market standing in the future.
See More
Kamada Receives FDA Approval for Plasma Sales in Texas
- FDA Approval: Kamada's plasma collection center in San Antonio, Texas, has received FDA approval, marking the commencement of commercial sales and significantly enhancing the company's competitive position in the plasma market.
- Annual Collection Capacity: The center has an annual collection capacity of approximately 50,000 liters of plasma, with projected annual revenues of $8 million to $10 million at full capacity, further strengthening the company's financial performance.
- Market Position Enhancement: The San Antonio center is expected to be one of the largest specialty plasma collection centers in the U.S., which not only elevates Kamada's market position but also lays the groundwork for future expansion.
- Future Development Plans: Following FDA approval, Kamada intends to seek subsequent inspection and approval from the European Medicines Agency, demonstrating its ambition for international expansion and commitment to the global market.
See More
KAMADA LTD - SAN ANTONIO CENTER AUTHORIZED TO START COMMERCIAL SALES OF NORMAL SOURCE PLASMA
- Commercial Sales Announcement: The Kamada San Antonio Center has been cleared to commence commercial sales of normal source plasma.
- Significance of Plasma Sales: This development marks a significant step in the center's operations, potentially impacting the supply of plasma-derived therapies.
See More
Kamada Receives FDA Approval for Plasma Collection Center in San Antonio, Texas
Announcement of New Facility: Kamada has announced the approval of its new plasma collection center in San Antonio, Texas.
Significance of the Center: The facility aims to enhance the company's capabilities in plasma collection, which is crucial for their therapeutic products.
See More
Major Averages Decline Amid Oil Price Volatility
- Market Impact from Oil Prices: The major averages, including the Dow, fell over 400 points as oil prices surged above $100 earlier in the week, reflecting traders' concerns over volatile energy prices and geopolitical tensions in the Middle East.
- IEA's Strategic Release: The International Energy Agency's decision to release approximately 400 million barrels from strategic reserves aims to stabilize energy markets following supply shocks due to conflicts, which could help mitigate extreme oil price fluctuations.
- Inflation Data Reaction: Recent inflation data showed a 0.3% month-over-month increase in the consumer price index and a 2.4% year-over-year rise, both aligning with consensus expectations, indicating persistent inflationary pressures that may influence future monetary policy decisions.
- Escalating Geopolitical Risks: U.S. forces sunk several Iranian ships near the Strait of Hormuz, heightening the fragility of global energy supply routes and contributing to unstable market sentiment, prompting investors to adopt a cautious stance regarding future market movements.
See More
